Journals / Fırat Tıp Dergisi / 2006 / Cilt: 11 - Sayı: 3

Effect of nebivolol treatment on P dispersion in hypertensive cases

Hipertansif olgularda nebivolol tedavisinin P dispersiyonu üzerine etkisi

Pages
154–159
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Six-month Nebivolol treatment markedly reduced P dispersion and homogenized atrial myocardium, which provides a basis for atrial arrhythmias.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Hypertension is a important cardiovascular risk factors that promotes the development of atrial fibrillation (AF).
📊
Key Findings & Data:Materials and Methods: The study included 65 patients (mean age 50.6±9.8; 31 males and 34 females) who were found to have essential hypertension.
💡
Conclusion & Impact:Results: Six-month Nebivolol treatment markedly reduced P dispersion and homogenized atrial myocardium, which provides a basis for atrial arrhythmias.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Elektrokardiyografi · Hipertansiyon · Electrocardiography

Abstract

Objectives: Hypertension is a important cardiovascular risk factors that promotes the development of atrial fibrillation (AF). Electrical heterogeneity and instability have been shown in the atrial conduction of hypertensive patients. P dispersion have been shown to be sensitive and specific noninvasive markers of atrial fibrillation. No study has been reported on the effect of Nebivolol on P dispersion. The objective of the present study is to Nebivolol treatment on the effect of P dispersion in hypertension of patient. Materials and Methods: The study included 65 patients (mean age 50.6±9.8; 31 males and 34 females) who were found to have essential hypertension. Biochemical parameters of all the patients in the study were analyzed, echocardiographies of all were taken and P dispersion was calculated in the ECG. All cases were put on 5 mg/day Nebivolol treatment. Biochemical parameter analyses, ECO and ECG were repeated in the 6th month. Results: Six-month Nebivolol treatment markedly reduced P dispersion and homogenized atrial myocardium, which provides a basis for atrial arrhythmias.

Özet

maç: Hipertansiyon atriyal fibrilasyon (AF) gelişimini artıran önemli kardiyovasküler risk faktörlerindendir. Hipertansif hastaların atriyal iletisinde, elektriksel heterojenite ve instabilite olduğu gösterilmiştir. P dispersiyonu atriyal fibrilasyonun sensitif ve spesifik non-invaziv belirteci olabileceği gösterilmiştir. Nebivolol’ün P dispersiyonu üzerine etkisini inceleyen çalışma bildirilmemiştir. Çalışmamızın amacı nebivolol tedavisinin P dispersiyonu üzerine etkilerini irdelemek idi. Gereç ve Yöntem: Bu çalışmaya esansiyel hipertansiyon saptanan 65 hasta (yaş ortalaması 50.6±9.8; 31 erkek; 34 kadın) alındı. Çalışmaya katılan tüm hastaların biyokimyasal parametreleri, ekokardiyografileri ve EKG’de P dispersiyonu hesaplandı. Tüm olgulara nebivolol 5 mgr/gün başlandı. Altıncı ay sonunda biyokimyasal parametreler, EKO ve EKG tekrarlandı. Bulgular: Olguların EKG’lerinde belirlenen bazal ve tedavi sonrası P dispersiyonu 55.3±6’dan 33.5±7’e (p=0.000) gerilemiştir. Bu olumlu klinik düzelme sol ventrikül diyastolik fonksiyonundaki düzelme ve kan basıncındaki azalma ile kolere olup, sol atriyum çapı ile kolere değildi. Sonuç: Altı aylık nebivolol tedavisi belirgin olarak P dispersiyonu azaltıp atriyal aritmilere zemin hazırlayan atriyal miyokardı homojen hale getirmiştir.

🔖

Cite This Article

DAĞLI, N., KARACA, I. (2006). Effect of nebivolol treatment on P dispersion in hypertensive cases. Fırat Tıp Dergisi, Cilt: 11 - Sayı: 3, 154–159. https://ajindex.com/articles/223802

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and redisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N–9N
  2. Levy S. Factors predisposing to the development of atrial fibrillation. PACE 1997;20:2670–74
  3. Calhoun DA, Bakir S, Oparil S. Etiology and pathogenesis of essential hypertension. Crawford MH, DiMarco JP. Cardiokogy. Mosby 2001 London pp. 3 1.1-3 1.10
  4. Tukek T, Akkaya V, Demirel S, Sozen AB, Kudat H, Atilgan D, et al. Effect of Valsalva maneuver on surface electrocardiographic P-wave dispersion in paroxysmal atrial fibrillation. Am J Cardiol 2000;85:896–99
  5. Aytemir K, Amasyali B, Abali G, Kose S, Kilic A, Onalan O, Tokgozoglu L, Kabakci G, Ozkutlu H, Nazli N, Isik E, Oto A. The signal-averaged P-wave duration is longer in hypertensive patients with history of paroxysmal atrial fibrillation as compared to those without. Int J Cardiol 2005;103(1):37–40
  6. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle.Circulation. 2004 Jun 15;109(23):2839-43
  7. Solti F, Vecsey T, Kekesi V, et al. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989;23:882–886
  8. Gersh BJ, Braunwald E, Bonow RO: Chronic coronary artery disease, in Braunwald E, Zipes DP, Libby P (eds): Heart Disease: A Textbook of Cardiovascular Medicine (ed 6). Philadelphia, PA, Saunders, 2001, p 1290
  9. Kawano S, Hiraoka M, Sawanobori T: Electrocardiographic features of p waves from patients with transient atrial fibrillation. Jpn Heart J 1988:29;57-67
  10. Dilaveris PE, Gialafos EJ, Sideris S, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998;135:733–38
  11. Devereux RB. Method of recognition and assesment of left ventricular hypertrophy. Medicographia 1995;17:12
  12. Devereux RB, De simone G, Schlussel CY. Echocardiographic left ventricular mass predicts risk of developing subseguent borderline hypertension. Am Coll Cardiol 1990;15:210-18
  13. Castellanos A, Kessler KM, Myerburg RJ. The resting electrocardiogram. In Alexander RW, Schlant RC, Fuster V. Hurst's The Heart, volume 1, USA, The McGraw-Hill Companies, 9 th edition, 1998; pp.371
  14. Brilla CG, Funck RC, Rupp H Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000 19;102(12):1388-93
  15. Mattioli AV, Bonatt